Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have been given an average rating of “Moderate Buy” by the eleven brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $128.91.
ORKA has been the subject of several recent analyst reports. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Piper Sandler reissued an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Wedbush set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 24th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, Guggenheim restated a “buy” rating and issued a $200.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th.
Get Our Latest Analysis on Oruka Therapeutics
Oruka Therapeutics Trading Down 2.1%
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, equities analysts forecast that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.
Insider Activity at Oruka Therapeutics
In related news, CEO Lawrence Klein sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $83.62, for a total value of $2,090,500.00. Following the completion of the transaction, the chief executive officer directly owned 923,128 shares of the company’s stock, valued at $77,191,963.36. This trade represents a 2.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 533 shares of Oruka Therapeutics stock in a transaction on Monday, September 21st. The stock was sold at an average price of $95.75, for a total value of $51,034.75. Following the transaction, the senior vice president directly owned 14,219 shares of the company’s stock, valued at approximately $1,361,469.25. This represents a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 137,951 shares of company stock worth $12,773,091 over the last three months. 23.49% of the stock is currently owned by corporate insiders.
Institutional Trading of Oruka Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of ORKA. BlackRock Inc. purchased a new position in shares of Oruka Therapeutics in the second quarter valued at $474,916,000. Jupiter Topco LLC purchased a new stake in Oruka Therapeutics during the 2nd quarter worth approximately $130,968,000. Bank of America Corp DE purchased a new position in shares of Oruka Therapeutics during the 2nd quarter valued at approximately $33,578,000. Braidwell LP bought a new stake in shares of Oruka Therapeutics in the second quarter worth $26,473,000. Finally, Atika Capital Management LLC acquired a new position in Oruka Therapeutics during the 1st quarter worth $11,277,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.
Oruka Therapeutics Company Profile
Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.
Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
